Abstract
Human β-defensin-2 (hBD2) is A small cationic peptide with A broad range of antimicrobial activity. An E. coli cell-free system was employed to express the hBD2 fusion protein by using the hBD2 gene with 14 rare codons. The results showed that the expression level of trxA-hBD2 fusion protein was 0.35 mg/ml, which is the same as that obtained with A synthetic codon-optimized gene. By using another fusion partner (GFP), similar high-level expression was also achieved in this cell-free system. This meant that human beta-defensin-2 gene could be directly used to express hBD2 fusion protein efficiently in an E. coli cell-free system without the optimization of codons. The expression level of hBD2 fused with thioredoxin could be further improved up to 2.0 mg/ml by adopting A continuous exchange cell-free system. A simple one-stage affinity purification procedure was also developed to recover this fusion protein efficiently.
Keywords: Human beta-defensin-2, cell-free system, codon usage, fusion protein, antimicrobial peptide, protein purification
Protein & Peptide Letters
Title: High-Level Expression of Human β-Defensin-2 Gene with Rare Codons in E. coli Cell-Free System
Volume: 13 Issue: 2
Author(s): Haiqin Chen, Zhinan Xu, Naizheng Xu and Peilin Cen
Affiliation:
Keywords: Human beta-defensin-2, cell-free system, codon usage, fusion protein, antimicrobial peptide, protein purification
Abstract: Human β-defensin-2 (hBD2) is A small cationic peptide with A broad range of antimicrobial activity. An E. coli cell-free system was employed to express the hBD2 fusion protein by using the hBD2 gene with 14 rare codons. The results showed that the expression level of trxA-hBD2 fusion protein was 0.35 mg/ml, which is the same as that obtained with A synthetic codon-optimized gene. By using another fusion partner (GFP), similar high-level expression was also achieved in this cell-free system. This meant that human beta-defensin-2 gene could be directly used to express hBD2 fusion protein efficiently in an E. coli cell-free system without the optimization of codons. The expression level of hBD2 fused with thioredoxin could be further improved up to 2.0 mg/ml by adopting A continuous exchange cell-free system. A simple one-stage affinity purification procedure was also developed to recover this fusion protein efficiently.
Export Options
About this article
Cite this article as:
Chen Haiqin, Xu Zhinan, Xu Naizheng and Cen Peilin, High-Level Expression of Human β-Defensin-2 Gene with Rare Codons in E. coli Cell-Free System, Protein & Peptide Letters 2006; 13 (2) . https://dx.doi.org/10.2174/092986606775101724
DOI https://dx.doi.org/10.2174/092986606775101724 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Immunotherapy for Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Microwave-Assisted Synthesis of N-Alkylated Bibenzoimidazolyl Derivatives: Antimicrobial Studies
Letters in Drug Design & Discovery Classification of Sarcomas Using Bioinformatics and Molecular Profiling
Current Pharmaceutical Biotechnology Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold
Medicinal Chemistry "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Current Pharmaceutical Design Evolution of the Scientific Literature of Cytochrome P450 from 1977 to 2008
Current Drug Metabolism Implication of Disulfide Bridge Induced Thermal Reversibility, Structural and Functional Stability for Luciferase
Protein & Peptide Letters Design, Synthesis and Biological Evaluation of Betulinic Acid Derivatives as New Antitumor Agents for Leukemia
Anti-Cancer Agents in Medicinal Chemistry Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Contribution of Transcriptome to Elucidate the Biology of Plasmodium spp
Current Topics in Medicinal Chemistry Synthesis, Characterization, Antimicrobial and Antitumor Activities of Sucrose Octa(N-ethyl)carbamate
Medicinal Chemistry Ultrasensitive Electrochemical Sensors for PSA Detection: Related Surface Functionalization Strategies
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Using Compound Similarity and Functional Domain Composition for Prediction of Drug-Target Interaction Networks
Medicinal Chemistry Aptamer-Based Fluorescent Biosensors
Current Medicinal Chemistry